Genetic Imaging Study With [tc-(99m)] Trodat-1 Spect in Adolescents With Adhd Using Oros-Methylphenidate
Loading...
Files
Date
2018
Journal Title
Journal ISSN
Volume Title
Publisher
Pergamon-Elsevier Science Ltd
Open Access Color
Green Open Access
No
OpenAIRE Downloads
OpenAIRE Views
Publicly Funded
No
Abstract
Aim: To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-(99m)] TRODAT-1SPECT in a sample of treatment-naive adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability. Methods: Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-(99m)] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day. Severity of illness was estimated using the Clinical Global Impression Scale (CGI-S) and DuPaul ADHD Rating Scale-Clinician version (ARS) before treatment,1 month and 2 months after initiating OROS-MPH treatment. Results: Decreased DAT availability was found in both the right caudate (pretreatment DAT binding: 224.76 +/- 33.77, post-treatment DAT binding: 208.86 +/- 28.75, p = 0.02) and right putamen (pre-treatment DAT binding: 314.41 +/- 55.24, post-treatment DAT binding: 285.66 +/- 39.20, p = 0.05) in adolescents with ADHD receiving OROS-MPH treatment. Adolescents with ADHD who showed a robust response to OROS-MPH (n = 7) had significantly greater reduction of DAT density in the right putamen than adolescents who showed less robust response to OROS-MPH (n = 13) (p = 0.02). However, between-group differences by treatment responses were not related with DAT density in the right caudate. Risk alleles (homozygosity for the 10-repeat allele of DAT1 gene) in the DAT1 gene were not associated with alterations in striatal DAT availability. Conclusion: Two months of OROS-MPH treatment decreased DAT availability in both the right caudate and putamen. Adolescents with ADHD who showed a robust response to OROS-MPH had greater reduction of DAT density in the right putamen. However,our findings did not support an association between homozygosity for a 10-repeat allele in the DAT1 gene and DAT density, assessedusing[Tc-(99m)] TRODAT-1SPECT.
Description
Keywords
ADHD, DAT1 gene, [Tc-(99m)] TRODAT-1 SPECT, OROS-methylphenidate, Deficit Hyperactivity Disorder, Dopamine-Transporter Gene, Attention-Deficit/Hyperactivity Disorder, Tc-99m-Trodat-1 Spect, Parkinsons-Disease, Children, Association, Adults, Psychostimulants, Availability, Male, Adolescent, OROS-methylphenidate, ADHD, Humans, Genetic Predisposition to Disease, DAT1 gene, [Tc-(99m)] TRODAT-1 SPECT, Psychiatric Status Rating Scales, Tomography, Emission-Computed, Single-Photon, Brain Mapping, Dopamine Plasma Membrane Transport Proteins, Homozygote, Brain, Organotechnetium Compounds, Treatment Outcome, Attention Deficit Disorder with Hyperactivity, Delayed-Action Preparations, Methylphenidate, Central Nervous System Stimulants, Female, Radiopharmaceuticals, Tropanes
Fields of Science
03 medical and health sciences, 0302 clinical medicine
Citation
WoS Q
Q1
Scopus Q
Q1

OpenCitations Citation Count
8
Source
Progress in Neuro-Psychopharmacology & Bıologıcal Psychıatry
Volume
86
Issue
Start Page
294
End Page
300
PlumX Metrics
Citations
CrossRef : 8
Scopus : 7
PubMed : 5
Captures
Mendeley Readers : 38
SCOPUS™ Citations
7
checked on Mar 22, 2026
Web of Science™ Citations
6
checked on Mar 22, 2026
Page Views
9
checked on Mar 22, 2026
Google Scholar™


